Altaris acquires Simulations Plus for $375M

Simulations Plus, Inc., a Durham-based global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, entered into a definitive agreement to be acquired by affiliates of Altaris, LLC, an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry, in an all-cash transaction. 

At or about the closing of the transaction, Altaris anticipates Simulations Plus will be combined with Chemical Computing Group (“CCG”), an existing Altaris portfolio company based in Montreal, Quebec, that provides advanced molecular design software to customers across the pharmaceutical, chemical and materials sectors.

Under the terms of the agreement, Simulations Plus common stockholders will receive $18.50 per share, representing a premium of 26% to Simulations Plus’ 60-day volume-weighted average price as of June 15, 2026.

“The life sciences industry is at an inflection point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models. This transaction provides immediate and certain value to Simulations Plus stockholders, and we believe the transaction will better position us to serve our customers and accelerate innovation across product offerings.” said Shawn O’Connor, Chief Executive Officer of Simulations Plus.

Upon completion of the transaction, Simulations Plus’ headquarters is expected to remain in Research Triangle Park, North Carolina. Upon closing, Simulations Plus will become a privately held subsidiary of Altaris and its common stock will no longer be traded on the Nasdaq Stock Exchange.